Neurotoxicity is one of the major pathological changes in multiple neurological disorders, including Alzheimer’s disease (AD) and Parkinson’s disease (PD), the second popular neurodegenerative disease in aged people. It is known that the AD and PD share the similar neuropathological hallmarks, such as the oxidative stress, loss of specific neurons, and aggregation of specific proteins. However, there are no effective therapeutic drugs for both AD and PD yet. Oxytocin (OXT) is a small peptide with 9 amino acids that is neuroprotective to many neurological disorders. Whether OXT administration confers neuroprotection to 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine (MPTP)-induced neurotoxicity in mice are still not known. In this study, we first found that the OXT levels are decreased in MPTP mice. Supplementation with OXT effectively rescues the locomotor disabilities and anxiety-like behaviors in MPTP mice. OXT also alleviates the hyperphosphorylation of α-synuclein at S129 site and the loss of dopaminergic neurons in the substantia nigra pars compacta, as well as the oxidative stress in the MPTP mice, and alleviates both oxidative stress and cell cytotoxicity in vitro. Furthermore, we found that OXT could inhibit the miR-26a/DAPK1 signal pathway in MPTP mice. In summary, our study demonstrates protective effects of OXT in MPTP mice and that miR-26a/DAPK1 signaling pathway may play an important role in mediating the protection of OXT.
BraakH, de VosRA, JansenEN, BratzkeH, BraakE (1998) Neuropathological hallmarks of Alzheimer’s and Parkinson’s diseases. Prog Brain Res117, 267–285.
5.
Bonito-OlivaA, MasiniD, FisoneG (2014) A mouse model of non-motor symptoms in Parkinson’s disease: Focus on pharmacological interventions targeting affective dysfunctions. Front Behav Neurosci8, 290.
6.
TieuK (2011) A guide to neurotoxic animal models of Parkinson’s disease. Cold Spring Harb Perspect Med1, a009316.
7.
TsigelnyIF, CrewsL, DesplatsP, ShakedGM, SharikovY, MizunoH, SpencerB, RockensteinE, TrejoM, PlatoshynO, YuanJX, MasliahE (2008) Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer’s and Parkinson’s diseases. PLoS One3, e3135.
8.
JellingerKA (2011) Interaction between alpha-synuclein and other proteins in neurodegenerative disorders. ScientificWorldJournal11, 1893–1907.
9.
BadiolaN, de OliveiraRM, HerreraF, Guardia-LaguartaC, GoncalvesSA, PeraM, Suarez-CalvetM, ClarimonJ, OuteiroTF, LleoA (2011) Tau enhances alpha-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS One6, e26609.
10.
FilichiaE, HofferB, QiX, LuoY (2016) Inhibition of Drp1 mitochondrial translocation provides neural protection in dopaminergic system in a Parkinson’s disease model induced by MPTP. Sci Rep6, 32656.
11.
MeredithGE, RademacherDJ (2011) MPTP mouse models of Parkinson’s disease: An update. J Parkinsons Dis1, 19–33.
12.
GerlachM, RiedererP (1996) Animal models of Parkinson’s disease: An empirical comparison with the phenomenology of the disease in man. J Neural Transm (Vienna)103, 987–1041.
13.
GerlachM, RiedererP, PrzuntekH, YoudimMB (1991) MPTP mechanisms of neurotoxicity and their implications for Parkinson’s disease. Eur J Pharmacol208, 273–286.
14.
DukaT, RusnakM, DroletRE, DukaV, WersingerC, GoudreauJL, SidhuA (2006) Alpha-synuclein induces hyperphosphorylation of tau in the MPTP model of parkinsonism. FASEB J20, 2302–2312.
15.
ZengXS, GengWS, JiaJJ (2018) Neurotoxin-induced animal models of Parkinson disease: Pathogenic mechanism and assessment. ASN Neuro10, 1759091418777438.
16.
SchmidtN, FergerB (2001) Neurochemical findings in the MPTP model of Parkinson’s disease. J Neural Transm (Vienna)108, 1263–1282.
17.
SchoberA (2004) Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res318, 215–224.
ErbasO, OltuluF, TaskiranD (2013) Suppression of exaggerated neuronal oscillations by oxytocin in a rat model of Parkinson’s disease. Gen Physiol Biophys32, 517–525.
20.
MillerTV, CaldwellHK (2015) Oxytocin during development: Possible organizational effects on behavior. Front Endocrinol (Lausanne)6, 76.
21.
BakosJ, StrbakV, RatulovskaN, BacovaZ (2012) Effect of oxytocin on neuroblastoma cell viability and growth. Cell Mol Neurobiol32, 891–896.
22.
LeunerB, CaponitiJM, GouldE (2012) Oxytocin stimulates adult neurogenesis even under conditions of stress and elevated glucocorticoids. Hippocampus22, 861–868.
23.
SarnyaiZ, KovacsGL (2014) Oxytocin in learning and addiction: From early discoveries to the present. Pharmacol Biochem Behav119, 3–9.
24.
KirschP (2015) Oxytocin in the socioemotional brain: Implications for psychiatric disorders. Dialogues Clin Neurosci17, 463–476.
25.
BarrazaJA, GrewalNS, RopackiS, PerezP, GonzalezA, ZakPJ (2013) Effects of a 10-day oxytocin trial in older adults on health and well-being. Exp Clin Psychopharmacol21, 85–92.
26.
BakouieF (2018) Intranasal spray of oxytocin might improve working memory performance in Alzheimer, tracking with diffusion tensor imaging. Biomed J Sci Tech Res9, 7216–7217.
27.
MichalopoulouPG, AverbeckBB, KalpakidouAK, EvansS, BobinT, KapurS, ShergillSS (2015) The effects of a single dose of oxytocin on working memory in schizophrenia. Schizophr Res162, 62–63.
28.
Jackson-LewisV, PrzedborskiS (2007) Protocol for the MPTP mouse model of Parkinson’s disease. Nat Protoc2, 141–151.
29.
Munoz-ManchadoAB, VilladiegoJ, Romo-MaderoS, Suarez-LunaN, Bermejo-NavasA, Rodriguez-GomezJA, Garrido-GilP, Labandeira-GarciaJL, EchevarriaM, Lopez-BarneoJ, Toledo-AralJJ (2016) Chronic and progressive Parkinson’s disease MPTP model in adult and aged mice. J Neurochem136, 373–387.
30.
ZhangL, ZhangL, LiL, HolscherC (2019) Semaglutide is neuroprotective and reduces alpha-synuclein levels in the chronic MPTP mouse model of Parkinson’s disease. J Parkinsons Dis9, 157–171.
31.
ListerRG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology92, 180–185.
LiuD, TangH, LiXY, DengMF, WeiN, WangX, ZhouYF, WangDQ, FuP, WangJZ, HebertSS, ChenJG, LuY, ZhuLQ (2017) Targeting the HDAC2/HNF-4A/miR-101b/AMPK pathway rescues tauopathy and dendritic abnormalities in Alzheimer’s disease. Mol Ther25, 752–764.
39.
YanH, PangP, ChenW, ZhuH, HenokKA, LiH, WuZ, KeX, WuJ, ZhangT, PanK, PeiL, HanY, LuY (2018) The lesion analysis of cholinergic neurons in 5XFAD mouse model in the three-dimensional level of whole brain. Mol Neurobiol55, 4115–4125.
40.
XieAJ, HouTY, XiongW, HuangHZ, ZhengJ, LiK, ManHY, HuYZ, HanZT, ZhangHH, WeiN, WangJZ, LiuD, LuY, ZhuLQ (2019) Tau overexpression impairs neuronal endocytosis by decreasing the GTPase dynamin 1 through the miR-132/MeCP2 pathway. Aging Cell18, e12929.
41.
NagarajanS, ChellappanDR, ChinnaswamyP, ThulasingamS (2015) Ferulic acid pretreatment mitigates MPTP-induced motor impairment and histopathological alterations in C57BL/6 mice. Pharm Biol53, 1591–1601.
42.
LeeKS, LeeJK, KimHG, KimHR (2013) Differential effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on motor behavior and dopamine levels at brain regions in three different mouse strains. Korean J Physiol Pharmacol17, 89–97.
43.
HeR, HuangW, HuangY, XuM, SongP, HuangY, XieH, HuY (2018) Cdk5 inhibitory peptide prevents loss of dopaminergic neurons and alleviates behavioral changes in an MPTP induced Parkinson’s disease mouse model. Front Aging Neurosci10, 162.
44.
VuckovicMG, WoodRI, HolschneiderDP, AbernathyA, TogasakiDM, SmithA, PetzingerGM, JakowecMW (2008) Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. Neurobiol Dis32, 319–327.
45.
CamposFL, CarvalhoMM, CristovaoAC, JeG, BaltazarG, SalgadoAJ, KimYS, SousaN (2013) Rodent models of Parkinson’s disease: Beyond the motor symptomatology. Front Behav Neurosci7, 175.
46.
WalkerDG, LueLF, AdlerCH, ShillHA, CavinessJN, SabbaghMN, AkiyamaH, SerranoGE, SueLI, BeachTG (2013) Changes in properties of serine 129 phosphorylated alpha-synuclein with progression of Lewy-type histopathology in human brains. Exp Neurol240, 190–204.
47.
TwohigD, NielsenHM (2019) alpha-synuclein in the pathophysiology of Alzheimer’s disease. Mol Neurodegener14, 23.
DiasV, JunnE, MouradianMM (2013) The role of oxidative stress in Parkinson’s disease. J Parkinsons Dis3, 461–491.
54.
PuspitaL, ChungSY, ShimJW (2017) Oxidative stress and cellular pathologies in Parkinson’s disease. Mol Brain10, 53.
55.
FengG, ZhangZ, BaoQ, ZhangZ, ZhouL, JiangJ, LiS (2014) Protective effect of chinonin in MPTP-induced C57BL/6 mouse model of Parkinson’s disease. Biol Pharm Bull37, 1301–1307.
56.
BurteF, De GirolamoLA, HargreavesAJ, BillettEE (2011) Alterations in the mitochondrial proteome of neuroblastoma cells in response to complex 1 inhibition. J Proteome Res10, 1974–1986.
MuralikrishnanD, MohanakumarKP (1998) Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEBJ12, 905–912.
59.
DluzenDE, McDermottJL, LiuB (1996) Estrogen alters MPTP-induced neurotoxicity in female mice: Effects on striatal dopamine concentrations and release. J Neurochem66, 658–666.
60.
GrunblattE, MandelS, BerkuzkiT, YoudimMB (1999) Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov Disord14, 612–618.
61.
KupschA, SautterJ, GotzME, BreithauptW, SchwarzJ, YoudimMB, RiedererP, GerlachM, OertelWH (2001) Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: Comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm (Vienna)108, 985–1009.
62.
PurbaJS, HofmanMA, SwaabDF (1994) Decreased number of oxytocin-immunoreactive neurons in the paraventricular nucleus of the hypothalamus in Parkinson’s disease. Neurology44, 84–89.
CiobicaA, BalmusIM, PadurariuM (2016) Is oxytocin relevant for the affective disorders?Acta Endocrinol (Buchar)12, 65–71.
65.
PadurariuM, AntiochI, BalmusI, CiobicaA, El-LetheyHS, KamelMM (2017) Describing some behavioural animal models of anxiety and their mechanistics with special reference to oxidative stress and oxytocin relevance. Int J Vet Sci Med5, 98–104.
66.
SakakibaraR, KishiM, OgawaE, TatenoF, UchiyamaT, YamamotoT, YamanishiT (2011) Bladder, bowel, and sexual dysfunction in Parkinson’s disease. Parkinsons Dis2011, 924605.
ShangT, JosephJ, HillardCJ, KalyanaramanB (2005) Death-associated protein kinase as a sensor of mitochondrial membrane potential: Role of lysosome in mitochondrial toxin-induced cell death. J Biol Chem280, 34644–34653.
71.
InbalB, BialikS, SabanayI, ShaniG, KimchiA (2002) DAP kinase and DRP-1 mediate membrane blebbing and the formation of autophagic vesicles during programmed cell death. J Cell Biol157, 455–468.
72.
GorbatyukOS, LiS, SullivanLF, ChenW, KondrikovaG, ManfredssonFP, MandelRJ, MuzyczkaN (2008) The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A105, 763–768.
73.
ChenL, FeanyMB (2005) Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci8, 657–663.
UttaraB, SinghAV, ZamboniP, MahajanRT (2009) Oxidative stress and neurodegenerative diseases: A review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol7, 65–74.
76.
BalmusI, CiobicaA, StoicaB, LefterR, CojocaruS, ReznikovA (2019) Effects of oxytocin administration on oxidative markers in the temporal lobe of aged rats. Neurophysiology51, 18–24.
77.
RashedLA, HashemRM, SolimanHM (2011) Oxytocin inhibits NADPH oxidase and P38 MAPK in cisplatin-induced nephrotoxicity. Biomed Pharmacother65, 474–480.
78.
SzetoA, NationDA, MendezAJ, Dominguez-BendalaJ, BrooksLG, SchneidermanN, McCabePM (2008) Oxytocin attenuates NADPH-dependent superoxide activity and IL-6 secretion in macrophages and vascular cells. Am J Physiol Endocrinol Metab295, E1495–1501.
79.
WangY, ZhaoS, LiuX, ZhengY, LiL, MengS (2018) Oxytocin improves animal behaviors and ameliorates oxidative stress and inflammation in autistic mice. Biomed Pharmacother107, 262–269.
80.
QuinnLP, PerrenMJ, BrackenboroughKT, WoodhamsPL, Vidgeon-HartM, ChapmanH, PangalosMN, UptonN, VirleyDJ (2007) A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: Pharmacological validation with R-(–)-deprenyl. J Neurosci Methods164, 43–49.
81.
QuinnLP, CrookB, HowsME, Vidgeon-HartM, ChapmanH, UptonN, MedhurstAD, VirleyDJ (2008) The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson’s disease through inhibition of monoamine oxidase B. Br J Pharmacol154, 226–233.
PiflC, GirosB, CaronMG (1993) Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J Neurosci13, 4246–4253.
84.
GermanDC, NelsonEL, LiangCL, SpecialeSG, SintonCM, SonsallaPK (1996) The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration5, 299–312.
85.
GiovanniA, SieberBA, HeikkilaRE, SonsallaPK (1991) Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J Pharmacol Exp Ther257, 691–697.
86.
SunstroE, StroI, TsutsumiT, OlsonL (1987) Studies on the effect of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57 BL/6 mice. Comparison with three other strains of mice. Brain Res405, 26–38.
87.
SedelisM, HofeleK, AuburgerGW, MorganS, HustonJP, SchwartingRK (2000) MPTP susceptibility in the mouse: Behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet30, 171–182.
88.
CherepanovSM, YokoyamaS, MizunoA, IchinoseW, LopatinaO, ShabalovaAA, SalminaAB, YamamotoY, OkamotoH, ShutoS, HigashidaH (2017) Structure-specific effects of lipidated oxytocin analogs on intracellular calcium levels, parental behavior, and oxytocin concentrations in the plasma and cerebrospinal fluid in mice. Pharmacol Res Perspect5, e00290.
89.
DecressacM, MattssonB, LundbladM, WeikopP, BjorklundA (2012) Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol Dis45, 939–953.
90.
PeelaertsW, BoussetL, Van der PerrenA, MoskalyukA, PulizziR, GiuglianoM, Van den HauteC, MelkiR, BaekelandtV (2015) alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature522, 340–344.
91.
LaurettiE, Di MecoA, MeraliS, PraticoD (2016) Chronic behavioral stress exaggerates motor deficit and neuroinflammation in the MPTP mouse model of Parkinson’s disease. Transl Psychiatry6, e733.
92.
OaksAW, FrankfurtM, FinkelsteinDI, SidhuA (2013) Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function. PLoS One8, e60378.
93.
PietropaoloS, FeldonJ, YeeBK (2014) Environmental enrichment eliminates the anxiety phenotypes in a triple transgenic mouse model of Alzheimer’s disease. Cogn Affect Behav Neurosci14, 996–1008.
94.
WeiZ, JunhongG, XiaoyuanN, JieW, ZhaojunW, MeinaW, WeiY, JunZ, JinshunQ (2017) Citalopram ameliorates impairments in spatial memory and synaptic plasticity in female 3xTgAD mice. Biomed Res Int2017, 1238687.
95.
ErbasO, ErgenogluAM, AkdemirA, YenielAO, TaskiranD (2013) Comparison of melatonin and oxytocin in the prevention of critical illness polyneuropathy in rats with experimentally induced sepsis. J Surg Res183, 313–320.
96.
IseriSO, SenerG, SaglamB, GedikN, ErcanF, YegenBC (2005) Oxytocin protects against sepsis-induced multiple organ damage: Role of neutrophils. J Surg Res126, 73–81.
AlizadehAM, FaghihiM, KhoriV, SohanakiH, PourkhaliliK, MohammadghasemiF, MohsenikiaM (2012) Oxytocin protects cardiomyocytes from apoptosis induced by ischemia-reperfusion in rat heart: Role of mitochondrial ATP-dependent potassium channel and permeability transition pore. Peptides36, 71–77.
